India Pesticides FY26 profit rises 45.8% to ₹120 crore
India Pesticides Limited reported a 45.8% increase in net profit to ₹120 crore for FY26, with revenue growing 27.9% to ₹1,078 crore, driven by domestic demand and operational efficiencies. The company recommended a dividend of ₹0.75 per share and provided FY27 guidance for 15-20% revenue growth, maintaining EBITDA margins of 18-20%.

*this image is generated using AI for illustrative purposes only.
India Pesticides Limited reported a net profit of ₹120 crore for the financial year ended March 31, 2026, an increase of 45.8% from ₹82 crore in the previous year. Revenue from operations for the year stood at ₹1,078 crore, compared to ₹843 crore in FY25. The performance was driven by strong domestic demand, volume growth, and improved operational efficiencies, with EBITDA increasing by 44.7% to ₹194 crore. Earnings per share (EPS) improved to ₹10.40 from ₹7.14 in the previous year. The Board of Directors has recommended a dividend of ₹0.75 per equity share of face value ₹1 each for the financial year ended March 31, 2026, subject to shareholder approval.
Financial Performance Overview
The following table summarises the consolidated financial performance for FY26:
| Metric (₹ In Cr.) | FY26 | FY25 | YoY % |
|---|---|---|---|
| Total Income | 1,078 | 843 | 27.9% |
| Net Profit (PAT) | 120 | 82 | 45.8% |
| EBITDA | 194 | — | 44.7% |
| EPS (₹) | 10.40 | 7.14 | — |
Quarterly Results
In the quarter ended March 31, 2026, net profit was ₹31 crore, compared to ₹22 crore in the same quarter last year. Total income for Q4 stood at ₹271 crore versus ₹211 crore in Q4 of the prior year. The quarterly results reflect a robust growth trajectory supported by higher demand for the company's product portfolio. EBITDA for the quarter increased to ₹46 crore from ₹35 crore in the corresponding quarter last year.
Key quarterly metrics are presented below:
| Metric (₹ In Cr.) | Q4 FY26 | Q4 FY25 | YoY % |
|---|---|---|---|
| Total Income | 271 | 211 | 28.5% |
| Net Profit (PAT) | 31 | 22 | 40.6% |
| EPS (Basic) (₹) | 2.66 | 1.89 | — |
Operational Highlights and Corporate Actions
The Technical & API segments continued to drive growth, contributing significantly to the total revenue. Management attributed the success to process optimization and backward integration. Domestic sales during Q4 FY26 increased significantly to ₹183 crore compared to ₹118 crore in the corresponding quarter last year, largely driven by strong demand for herbicides and intermediates. The company achieved approximately 30% volume growth during the quarter.
The Board of Directors, at its meeting on May 23, 2026, approved the audited financial results and re-appointed M/s Honey Singh & Associates, Cost Accountants, as the Cost Auditor for the financial year 2026-27. The company also re-appointed M/s Seth & Associates, Chartered Accountants, as the Internal Auditor. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors, M/s Suresh Surana & Associates LLP, issued an audit report with an unmodified opinion on the standalone and consolidated annual financial results for the year ended March 31, 2026. The record date for determining eligibility for the dividend payment is August 24, 2026.
Conference Call and Future Outlook
During the earnings conference call held on May 25, 2026, management highlighted that the company crossed the ₹1,000 crore revenue mark for the first time. Export revenues contributed approximately 39% of total revenues during FY26. The company commissioned an intermediate plant towards backward integration and is developing the Hamirpur facility for future capacity expansion. Formulation capacity has scaled up to 10,000 metric tonnes.
For FY27, the company expects a revenue increase of 15% to 20% and aims to maintain EBITDA margins between 18% and 20%. The Capex budget for 2026-27 is ₹45 crore for India Pesticides and ₹90 crore for its 100% subsidiary, funded primarily through internal accruals. Management reiterated its long-term guidance to achieve ₹3,000 crore revenue by March 2031, with the Shalvis facility expected to contribute approximately ₹1,000 crore by then.
How will the company manage the projected 15-20% revenue growth in FY27 amidst potential market volatility?
What impact will the new Hamirpur facility and Shalvis expansion have on long-term production capacity and margins?
How might the dividend payout ratio evolve given the increased Capex plans for FY27?

































